Drugs that block cancer blood vessel growth (anti angiogenics)

Anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. This might slow the growth of the cancer or sometimes shrink it. 

There are different types of anti angiogenic drugs. These work in different ways. 

What is anti angiogenesis treatment?

Solid tumours Open a glossary item need a good blood supply to provide itself with food and oxygen and to remove waste products. When it has reached 1 to 2 mm across, a tumour needs to grow its own blood vessels in order to continue to get bigger.

Angiogenesis means the growth of new blood vessels. So anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it.

How does cancer grow its own bloody supply?

Some cancer cells make a protein called vascular endothelial growth factor (VEGF). The VEGF protein attaches to receptors on cells that line the walls of blood vessels within the tumour. The cells are called endothelial cells. This triggers the blood vessels to grow so the cancer can then grow.

Types of anti angiogenesis treatment

There are different types of drugs that block blood vessel growth:

Drugs that block blood vessel growth

Some drugs block vascular endothelial growth factor (VEGF) from attaching to the receptors on the cells that line the blood vessels. This stops the blood vessels from growing.

An example of a drug that blocks VEGF is bevacizumab (Avastin). Bevacizumab is also a monoclonal antibody. It is a treatment for several different types of cancer. Other examples include:

  • aflibercept
  • ramucirumab

Drugs that block signalling within the cell

Some drugs stop the VEGF receptors from sending growth signals into the blood vessel cells. These treatments are also called cancer growth blockers or tyrosine kinase inhibitors (TKIs).

Examples of TKIs that block signals inside blood vessels cells include:

  • sunitinib 
  • sorafenib
  • axitinib
  • regorafenib
  • cabozantinib
  • pazopanib
  • lenvatinib

Drugs that affect signals between cells

Some drugs act on the chemicals that cells use to signal to each other to grow. This can block the formation of blood vessels.

Drugs that works in this way include thalidomide and lenalidomide (Revlimid). They are used to treat some people with multiple myeloma.

How you have anti angiogenic treatment

How you have the treatment, how often you have it and for how long depends on:

  • which drug you have
  • the type of cancer you have

You take some anti angiogenic drugs as tablets or capsules which you swallow once or twice a day.

Or you might have it through a drip (infusion) into a vein.

Side effects of anti angiogenesis treatment

All treatments can cause side effects. The side effects vary for each individual drug and from person to person. The side effects can also depend on what other treatments you’re having.

Find out more about the side effects of each drug by following the link to our cancer drugs A to Z list.

  • Antiangiogenic therapy in oncology: current status and future directions
    GC Jayson and others
    Lancet, 2016. Volume 388, Number 10043, Pages 518 to 29

  • Cancer: Principles and Practice of Oncology (12th edition)
    VT DeVita, TS Lawrence, SA Rosenberg
    Wolters Kluwer, 2023

  • Trends and Challenges in Tumor Anti-Angiogenic Therapies
    J Jászai and M H H Schmidt
    Cells, September 2019. Volume 8, Issue 9, Page 1102

  • Clinical development of targeted and immune based anti-cancer therapies
    N A Seebacher and others
    Journal of Experimental Clinical Cancer Research, April 2019. Volume 38, Issue 1, Page 156

  • The Role of Angiogenesis in Cancer Treatment
    M. Rajabi and SA. Mousa
    Biomedicines, 2017. Volume 5, Issue 2 

  • The information on this page is based on literature searches and specialist checking. We used many references and there are too many to list here. If you need additional references for this information please contact patientinformation@cancer.org.uk with details of the particular issue you are interested in.

Last reviewed: 
24 Sep 2024
Next review due: 
24 Sep 2027

Related links